Coronavirus breakthrough by INRS researchers

November 10, 2015

Quebec researchers have discovered that a mutation in a coronavirus protein slows the spread of the virus in the central nervous system and reduces its neurovirulence. It is the first time that this phenomenon has been observed in the coronavirus family, which is responsible for one-third of common colds and is also suspected of being associated with the development or aggravation of neurological diseases such as multiple sclerosis, Alzheimer's disease, and encephalitis. The discovery, which has just been published in the prestigious journal PLoS Pathogens, was achieved in the Laboratory of Neuroimmunovirology at INRS-Institut Armand-Frappier.

In analyzing more than 60 human respiratory tract samples from patients infected by the human coronavirus, researchers discovered an important mutation in the S protein that modifies the virus capacity to infect nerve cells. The mutation is associated with the degree of viral virulence.

"We noticed that the protein mutation did not affect the virus's ability to infect the central nervous system, but that the mutated virus was less pathogenic and neurovirulent, probably as a result of changes in the way it spread from neuron to neuron due to the action of cellular proteins known as proprotein convertases, which alter the structure of the viral protein," explained lead researcher Professor Pierre Talbot. "Under these conditions, the coronavirus could more easily cause a persistent central nervous system infection. In virology, this phenomenon is known to trigger certain slow-developing neurological conditions or aggravate neurological diseases"

These results make it possible to better understand how persistent coronavirus infections take hold and may help prevent the development of associated neurological diseases in humans.
-end-
About the article

This research was conducted by first co-authors Alain Le Coupanec, doctoral candidate, and Marc Desforges, research associate, and by Mathieu Meessen-Pinard, doctoral candidate, and Mathieu Dubé, postdoctoral fellow, all from the INRS Laboratory of Neuroimmunovirology; Robert Day, professor at Université de Sherbrooke; Nabil Seidah, professor at IRCM; and Pierre Talbot, professor and director of the Laboratoiy of Neuroimmunovirology at INRS-Institut Armand-Frappier, and corresponding author. The results of their work have been published in the journal PLoS Pathogens under the title "Cleavage of a neuroinvasive human respiratory virus spike glycoprotein by proprotein convertases modulates neurovirulence and virus spread within the central nervous system" (DOI: 10.1371/journal.ppat.1005261). The research was supported by grants from the Canadian Institutes of Health Research, a Senior Canada Research Chair held by Pierre Talbot, and fellowships from Fonds de recherche Québec - Santé and Fondation universitaire Armand-Frappier de l'INRS.

About INRS

INRS is a graduate-level research and training university and ranks first in Canada for research intensity (average grant funding per faculty member). INRS brings together some 150 professors and close to 700 students and postdoctoral fellows at its four centres in Montreal, Quebec City, Laval, and Varennes. Its applied and fundamental research is essential to the advancement of science in Quebec and internationally even as it plays a key role in the development of concrete solutions to the problems faced by our society.

Institut national de la recherche scientifique - INRS

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.